Eurofins Scientific SE · EURONEXT:ERF
Eurofins Scientific — Q3 2021 Earnings Presentation
12 slides from Eurofins Scientific's earnings presentation, Oct 21, 2021
Slide 1: Q3 2021 Management Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key financial highlights
Key financial highlights Revenues, EUR m Key Highlights 1,630 • Strong revenue growth in Q3 of EUR 1,630m, +14.6% year-on-year • Organic growth2 of 11.7% in Q3 2021 vs. Q3 2020 reflecting resilience of Core Business 3 1,423 and significant contribution from COVID-19 related activities • Core Busines
Slide 4: Key operational highlights
Key operational highlights • Continued strong growth across business lines and geographies • Global demand for BioPharma services remains very strong • Pharmaceutical companies continue to outsource increasing amount of testing services and Eurofins is actively expanding capacity across its laborato
Slide 5: COVID-19 related business developments: innovation and product launches continue
COVID-19 related business developments: innovation and product launches continue • Remained very active in fighting the pandemic throughout Q3 2021 as COVID testing continues at significant levels • Won the Singapore Food Agency SARS-CoV-2 virus surface swabs testing project tender • Greater proport
Slide 6: Our ESG targets and roadmap
Our ESG targets and roadmap 1. Established Sustainability and Corporate Governance Committee (Board level) and Executive Sustainability Committee; 2. ESG targets into leadership performance and remuneration for all Business 2020 2021 Y-o-Y Rating agency Scale Rating Rating Change Units leader and mo
Slide 7: Outlook
Outlook • Eurofins completed 28 acquisitions in NM 2021 which generated revenues of over EUR 160m for FY 2020 • Eurofins M&A pipeline remains substantial although we stay very selective and disciplined to create significant long-term value • Eurofins is upgrading its FY 2021 revenue objective to EUR
Slide 8: Conclusions
Conclusions • Core Business1 delivered strong organic growth of about 9% in Q3 2021 and about 14% in NM 2021 • Continue to see robust demand for COVID testing services, with additional new contracts won in Canada and Singapore • Continued investments in the Group’s laboratory network and IT systems
Slide 9: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited.
Slide 10: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited.
Slide 11: Segment performance
Segment performance Δ in Segment Key Highlights Revenues Revenues Revenues (in EUR m except As % of total As % of total NM 2021 NM 20201 NM 2021 vs. otherwise stated) NM 2020 • Strong growth of revenues in Europe of 39.9% to EUR 2,939m vs. NM 2020: Europe 2,939 60.0% 2,101 56.1% 39.9% o Expanding Bi
Slide 12: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and re